Agenus Inc. [NASDAQ: AGEN] gained 9.16% or 0.25 points to close at $2.92 with a heavy trading volume of 4726409 shares. The company report on April 19, 2021 that Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer.
Submission has been made for review under the accelerated approval pathway.
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). The BLA has been submitted for the accelerated approval of balstilimab, Agenus’ anti-PD-1 antibody, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, and includes data from its pivotal Phase 2 single-arm clinical trial, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. These clinical data, along with preclinical data, suggest that balstilimab demonstrates differentiated features from other anti-PD-1 antibodies.
It opened the trading session at $2.67, the shares rose to $2.92 and dropped to $2.62, the range by which the price of stock traded the whole day. The daily chart for AGEN points out that the company has recorded -30.48% loss over the past six months. However, it is still -28.07% lower than its most recent low trading price.
If we look at the average trading volume of 3.93M shares, AGEN reached to a volume of 4726409 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Agenus Inc. [AGEN]:
B. Riley FBR have made an estimate for Agenus Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 19, 2019. The new note on the price target was released on April 22, 2019, representing the official price target for Agenus Inc. stock. Previously, the target price had yet another drop from $10 to $5, while H.C. Wainwright kept a Neutral rating on AGEN stock.
The Average True Range (ATR) for Agenus Inc. is set at 0.19, with the Price to Sales ratio for AGEN stock in the period of the last 12 months amounting to 6.88.
Trading performance analysis for AGEN stock
Agenus Inc. [AGEN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.55. With this latest performance, AGEN shares dropped by -8.46% in over the last four-week period, additionally sinking by -30.48% over the last 6 months – not to mention a rise of 3.18% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGEN stock in for the last two-week period is set at 49.94, with the RSI for the last a single of trading hit 58.36, and the three-weeks RSI is set at 46.25 for Agenus Inc. [AGEN]. The present Moving Average for the last 50 days of trading for this stock 3.39, while it was recorded at 2.69 for the last single week of trading, and 3.73 for the last 200 days.
Agenus Inc. [AGEN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Agenus Inc. [AGEN] shares currently have an operating margin of -340.25. Agenus Inc.’s Net Margin is presently recorded at -434.14.
Reflecting on the efficiency of the workforce at the company, Agenus Inc. [AGEN] managed to generate an average of -$543,170 per employee. Receivables Turnover for the company is 35.49 with a Total Asset Turnover recorded at a value of 0.27.Agenus Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 0.90.
Agenus Inc. [AGEN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Agenus Inc. posted -0.31/share EPS, while the average EPS was predicted by analysts to be reported at -0.33/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 6.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AGEN.
An analysis of insider ownership at Agenus Inc. [AGEN]
There are presently around $284 million, or 52.40% of AGEN stock, in the hands of institutional investors. The top three institutional holders of AGEN stocks are: BLACKROCK INC. with ownership of 14,517,609, which is approximately 7.687% of the company’s market cap and around 0.40% of the total institutional ownership; RTW INVESTMENTS, LP, holding 12,864,677 shares of the stock with an approximate value of $34.41 million in AGEN stocks shares; and ORACLE INVESTMENT MANAGEMENT INC, currently with $31.7 million in AGEN stock with ownership of nearly -9.764% of the company’s market capitalization.
Positions in Agenus Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 64 institutional holders increased their position in Agenus Inc. [NASDAQ:AGEN] by around 12,212,238 shares. Additionally, 52 investors decreased positions by around 7,925,968 shares, while 39 investors held positions by with 86,163,837 shares. The mentioned changes placed institutional holdings at 106,302,043 shares, according to the latest SEC report filing. AGEN stock had 16 new institutional investments in for a total of 222,192 shares, while 13 institutional investors sold positions of 1,354,722 shares during the same period.